Praxis Precision Medicines 

Yahoo Finance • 3 months ago

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

Praxis Precision Medicines, Inc. BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for cen... Full story

Yahoo Finance • 12 months ago

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last year

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last year

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last year

Praxis Precision Medicines Inc (PRAX) Reports Q3 2023 Financial Results

Praxis Precision Medicines Inc (NASDAQ:PRAX) reported a net loss of $24.6 million for Q3 2023, a decrease from $43.9 million for the same period in 2022. The company's cash and cash equivalents stood at $101.1 million as of September 30, 2... Full story

Yahoo Finance • last year

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing development Cash of $101.1 million as of September 30... Full story

Yahoo Finance • last year

Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last year

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter... Full story

Yahoo Finance • last year

Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disord... Full story

Yahoo Finance • last year

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS International Congress

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last year

Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities

Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to evaluate PRAX-628 expected to read-out by YE... Full story

Yahoo Finance • last year

Praxis Precision Medicines, Inc. Announces Pricing of $59.1 Million Public Offering

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last year

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorde... Full story

Yahoo Finance • last year

Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA

Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60 mg/day dose to be tested BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:... Full story

Yahoo Finance • 2 years ago

Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile

PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider than current market leader based on MES mo... Full story

Yahoo Finance • 2 years ago

Praxis Precision Medicines to Present at the American Academy of Neurology 2023 Annual Meeting

BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disord... Full story

Yahoo Finance • 2 years ago

Praxis Precision Medicines Announces Upcoming Ulixacaltamide Presentations & Events

BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disord... Full story

Yahoo Finance • 2 years ago

Praxis Precision Medicines to Present at 22nd Annual Needham Virtual Healthcare Conference

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disord... Full story

Yahoo Finance • 2 years ago

Praxis Precision Medicines to Present at Upcoming Investor Conferences

BOSTON, March 03, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disord... Full story

Yahoo Finance • 2 years ago

Praxis Precision Medicines Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3

Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in 2H23 Ulixacaltamide demonstrated impr... Full story